Tango Therapeutics (NASDAQ:TNGX – Get Rating) is one of 965 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Tango Therapeutics to similar businesses based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, dividends and valuation.
Volatility & Risk
Tango Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Tango Therapeutics’ peers have a beta of 0.95, indicating that their average stock price is 5% less volatile than the S&P 500.
This table compares Tango Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tango Therapeutics Competitors||-3,200.28%||-120.34%||-23.13%|
Valuation and Earnings
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Tango Therapeutics||$37.04 million||-$58.24 million||-6.90|
|Tango Therapeutics Competitors||$1.81 billion||$243.57 million||-5.84|
Tango Therapeutics’ peers have higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings and target prices for Tango Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tango Therapeutics Competitors||3353||13447||39566||658||2.66|
As a group, “Pharmaceutical preparations” companies have a potential upside of 104.25%. Given Tango Therapeutics’ peers higher probable upside, analysts plainly believe Tango Therapeutics has less favorable growth aspects than its peers.
Institutional and Insider Ownership
80.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 41.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 3.7% of Tango Therapeutics shares are held by company insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Tango Therapeutics beats its peers on 7 of the 13 factors compared.
Tango Therapeutics Company Profile
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.